Skip to main content

Table 5 Backward logistic regression of factors involved in nevirapine induced liver toxicity

From: Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy

  OR (95%CI) p aOR (95%CI) p
Male vs Female 0.19 (0.04–0.94) 0.042 0.27 (0.06–1.30) 0.102
Age (× 1 year more) 0.96 (0.88–1.04) 0.293  
MSM vs HE 0.24 (0.01–4.51) 0.338  
IVDUs vs HE 2.20 (0.58–8.41) 0.247  
Other vs HE 1.36 (0.06–29.16) 0.844  
Caucasian vs Non-Caucasian 0.67 (0.08–5.64) 0.714  
BMI (× 1 more) 0.70 (0.51–0.94) 0.020 0.72 (0.52–1.00) 0.050
Previous AIDS 0.67 (0.08–5.56) 0.713  
Previous therapy duration (× 1 year more) 1.05 (0.90–1.23) 0.518  
CD4 200–500 cell/μL vs < 200 cell/μL 1.17 (0.05–25.7) 0.920 1.51 (0.07–32.23) 0.790
CD4 > 500 cell/μL vs < 200 cell/μL 3.97 (0.21–74.51) 0.357 8.12 (0.42–156.90) 0.166
HIV-RNA (× 1 log10 more) 0.80 (0.54–1.18) 0.260  
AST (× 1 more) 1.02 (1.01–1.03) 0.008 1.01 (0.99–1.03) 0.144
ALT (× 1 more) 1.01 (1.00–1.02) 0.015  
HCV coinfection 6.93 (1.38–34.87) 0.019 8.00 (1.27–50.29) 0.027
HBV coinfection 2.39 (0.28–20.36) 0.427  
ARV Backbone: AZT/DDI/D4T vs ABC 0.73 (0.12–4.47) 0.731  
ARV Backbone: TDF vs ABC 0.12 (0.01–3.141) 0.204  
ARV Backbone: Other vs ABC 0.49 (0.02–13.47) 0.672  
ABCB1 rs1045642 CT/TT vs CC 0.18 (0.04–0.76) 0.020 0.10 (0.02–0.47) 0.004
  1. Abbreviations: OR Odds Ratio, aOR adjusted Odds Ratio, CI confidence interval, HE Heterosexual, MSM Man how have sex with man, IVDUs Intra venous drug users, BMI Body Mass Index, cps copies, ABC abacavir, TDF tenofovir diproxil fumarate, BMI Body Mass Index, ABCB ATP Binding Cassette Subfamily B